Skip to main content

Table 1 Performance characteristics of careHPV assay for the detection of 14 high-risk (hr) HPV genotypes compared with HPV genotyping among 175 women in Cape Coast, Ghana

From: Options in human papillomavirus (HPV) detection for cervical cancer screening: comparison between full genotyping and a rapid qualitative HPV-DNA assay in Ghana

 

All women (N = 175)

% (95% CI)

HIV-1 seropositive women (N = 94)

% (95% CI)

HIV seronegative women (N = 81)

% (95% CI)

* P-value

hr-HPV prevalence

55.0 (48.0–62.9)

79.0 (69.0–86.5)

28.0 (19.0–39.5)

0.0001

Sensitivity

96.9 (91.2–99.4)

97.3 (90.6–99.7)

95.7 (78.1–99.9)

0.50

Specificity

91.0 (82.4–96.3)

85.0 (62.1–96.8)

93.1 (83.3–98.1)

0.10

PPV

93.1 (86.2–97.2)

96.0 (88.8–99.2)

84.6 (65.1–95.6)

0.01

NPV

95.9 (88.8–99.2)

89.5 (66.9–98.7)

98.2 (90.3–100.0)

0.02

Agreement

94.3 (89.7–97.2)

94.7 (88.0–98.3)

93.8 (86.2–98.0)

0.77

Kappa value (95%CI)

0.88 (0.81–0.95)

0.84 (0.70–0.98)

0.85 (0.73–0.98)

0.86

P-value for Kappa

<0.0001

<0.0001

<0.0001

 
  1. PPV positive predictive valuem, NPV negative predictive value
  2. * comparing HIV-1 seropositive and HIV-seronegative women